Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company advancing targeted therapies for endocrine-driven breast cancers. This page provides investors and healthcare professionals with timely updates on clinical developments, financial disclosures, and strategic initiatives.
Access consolidated information about OLMA's lead candidate palazestrant (OP-1250), an oral complete estrogen receptor antagonist/SERD, and other pipeline assets like the KAT6 inhibitor OP-3136. Track regulatory milestones, partnership announcements, and peer-reviewed research findings in one centralized location.
Key updates include clinical trial progress, scientific conference presentations, and financial results. All content is sourced from official company communications and verified industry reports to ensure accuracy.
Bookmark this page for streamlined access to OLMA's latest developments in women's oncology therapeutics. Check regularly for essential updates impacting treatment innovation and corporate strategy.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the grant of stock options totaling 58,300 shares to four new employees, effective October 3, 2022. These options were approved by the Board’s Compensation Committee under the 2022 Inducement Plan, with a 10-year term and an exercise price of $2.91 per share. The options vest over four years, with 25% vesting on the first anniversary and the rest in monthly installments. This move aligns with Nasdaq Listing Rule 5635(c)(4) and underscores Olema's commitment to attracting talent in the competitive biotech landscape.
Olema Pharmaceuticals (Nasdaq: OLMA) announced that Shane Kovacs, COO and CFO, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 2:30 p.m. ET. A live webcast of the chat will be available on Olema's website and archived for 14 days. Olema, focused on therapies for women's cancers, is advancing its lead product candidate, OP-1250, an estrogen receptor antagonist and degrader, in clinical trials for ER-positive breast cancer.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, has announced the granting of stock options to three new employees. Effective September 1, 2022, a total of 72,200 shares will be available for purchase at an exercise price of $3.69 per share, equivalent to the last reported sale price on that date. The stock options will vest over four years, with 25% vesting after one year and the remainder in monthly installments, contingent on continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals has received Fast Track designation from the FDA for OP-1250, targeting ER+/HER2- metastatic breast cancer.
The company reported a strong cash position of $240.7 million as of June 30, 2022, sufficient to support operations until the second half of 2024.
Despite a net loss of $32.9 million in Q2 2022, up from $16.4 million the previous year, Olema continues to advance its clinical development program, having selected a recommended Phase 2 dose of 120 mg for OP-1250.
Olema Pharmaceuticals has moved OP-1250, a complete estrogen receptor antagonist and selective ER degrader, into Phase 2 clinical development for ER+/HER2- metastatic breast cancer. Phase 1b expansion results noted encouraging anti-tumor activity with 4 partial responses observed among 31 evaluable patients. 50 patients received treatment at two dose levels. The recommended Phase 2 dose is set at 120 mg once daily. Enrollment in Phase 2 includes distinct cohorts, and a pivotal trial is planned for mid-2023.
Olema Pharmaceuticals (Nasdaq: OLMA) announced that its CEO, Sean P. Bohen, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 1:30 p.m. ET. A live webcast of the event will be available on Olema's website, where it will be archived for 14 days.
Olema is focused on developing targeted therapies for women’s cancers, with its lead candidate, OP-1250, currently in clinical trials for treating ER-positive, HER2-negative breast cancer.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced the grant of stock options to a new employee for 70,000 shares, effective August 1, 2022. This award, approved by the Compensation Committee, is part of the 2022 Inducement Plan. The options vest over four years, starting with 25% on the first anniversary and the rest in monthly installments. The exercise price is $4.95 per share, matching the stock's last reported sale price. Olema focuses on targeted therapies for women’s cancers, with its lead product, OP-1250, currently in clinical trials for ER-positive breast cancer.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced that the FDA granted Fast Track designation to its drug OP-1250, a novel oral complete estrogen receptor antagonist and selective ER degrader, for treating ER-positive, HER2-negative metastatic breast cancer. This designation aims to expedite development and review processes, allowing for closer communication with the FDA. OP-1250 is currently in a Phase 1/2 clinical trial and being evaluated in combination with palbociclib. Fast Track designation represents a significant milestone for Olema in addressing unmet medical needs in women's cancer treatments.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced the grant of stock options to three new employees for a total of 32,000 shares, effective July 1, 2022. Approved by the Compensation Committee, the stock options are part of the 2022 Inducement Plan, vesting over four years with a 10-year term and an exercise price of $4.18 per share. The company aims to attract talent critical for its focus on developing targeted therapies for women's cancers, including its lead candidate, OP-1250, currently in clinical trials for treating ER-positive breast cancer.
Olema Pharmaceuticals reported promising clinical advancements for OP-1250, its compound targeting ER+ / HER2- breast cancer. The Phase 1b study demonstrated favorable tolerability with no grade 3/4 neutropenia and early anti-tumor activity. OP-1250's combinability with palbociclib was confirmed, showing no dose limiting toxicities. Olema plans a pivotal study for OP-1250 in 2023, aiming for continued enrollment in clinical trials through 2024. High enthusiasm from investigators contributed to rapid patient recruitment, reflecting confidence in the candidate's potential.
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
